Pneumagen announced that a Phase 2 challenge study Neumifil multivalent carbohydrate binding module (mCBM) nasal spray against influenza met its primary endpoints, demonstrating statistically significant reductions in the rate of infection and in symptom severity compared to placebo. The initiation of the challenge study was announced in August 2022.
The company says that it will now proceed with additional studies, including a planned Phase 2b trial in COPD patients experiencing exacerbations caused by viral infection. Earlier this year, Pneumagen announced that it had raised £8 million to support that trial.
Pneumagen CEO Douglas Thomson commented, “We are extremely pleased that this Phase 2 proof of concept study met all of its key objectives. The positive and clinically meaningful results we have delivered mark a critical step forward in the development of Neumifil and substantiate Pneumagen’s commitment to delivering a novel treatment option for patients suffering from virus induced exacerbations of respiratory diseases. These excellent results mean we can progress Neumifil with great confidence into further clinical studies to explore the efficacy and safety profile of our novel drug candidate in a larger at risk COPD patient population.”
Read the Pneumagen press release.
